[{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"Methodist Hospitals"},"Description\n":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis","Condition Tag":null,"PI":"William L. Conte, MD, MS","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT05156281?cond=Multiple%20Sclerosis&intr=remibrutinib&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"Methodist Hospitals"},"Description\n":"Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis","Condition Tag":null,"PI":"William L. Conte, MD, MS","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT06141473?cond=Multiple%20Sclerosis&intr=frexalimab&rank=2"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"Methodist Hospitals"},"Description\n":"Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis","Condition Tag":null,"PI":"William L. Conte, MD, MS","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT06141486?cond=Multiple%20Sclerosis&term=FREVIVA&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Endeavor Northshore"},"Description\n":"A randomized, open label, multi-center, active-comparator study to assess the efficacy, safety and tolerability of ofatumumab 20mg sc monthly versus continued current therapy in relapsing-remitting multiple sclerosis after elevation of serum neurofilament light levels.","Condition Tag":null,"PI":"Carolyn Goldschmidt, DO","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT05090371?term=SOSTOS&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Endeavor Northshore"},"Description\n":"Master protocol of two Phase 3, randomized, double-blind efficacy and safety studies comparing frexalimab (SAR441344) to teriflunomide (Aubagio) in adult participants with relapsing forms of multiple sclerosis.","Condition Tag":null,"PI":"Afif Hentati, MD","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT06141473?cond=Multiple%20Sclerosis&intr=frexalimab&rank=2"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Endeavor Northshore"},"Description\n":"Performance and safety of a digital tool for the unsupervised self-assessment of neuromyelitis optica spectrum disorder.","Condition Tag":null,"PI":"Afif Hentati, MD","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT05566769?term=OPTIS&rank=3"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":1,"Value":"Endeavor Northshore"},"Description\n":"A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)","Condition Tag":null,"PI":"Carolyn Goldschmidt, DO","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT06433752?term=ENABLE&intr=Ublituximab&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Description\n":"Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis","Condition Tag":null,"PI":"Tom Shoemaker, MD","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT05156281?cond=Multiple%20Sclerosis&intr=remibrutinib&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Description\n":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis","Condition Tag":null,"PI":"Tom Shoemaker, MD ","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT03500328?term=TREAT-MS&rank=2"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Description\n":"Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis","Condition Tag":null,"PI":"Tom Shoemaker, MD","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT06141486?cond=Multiple%20Sclerosis&term=FREVIVA&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Description\n":"Comparison Between ABP 692 and Ocrevus","Condition Tag":null,"PI":"Tom Shoemaker, MD","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT06700343?term=Comparison%20Between%20ABP%20692%20and%20Ocrevus&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Description\n":"Study to Evaluate Efficacy of a Modified Regimen of Ublituximab","Condition Tag":null,"PI":"Tom Shoemaker, MD","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT05877963?term=enhance&intr=Ublituximab&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Description\n":"A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis","Condition Tag":null,"PI":"Fabian Sierra-Morales, MD","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT06433752?term=ENABLE&intr=Ublituximab&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":2,"Value":"Rush University"},"Description\n":"A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib.","Condition Tag":null,"PI":"Allison Osen, MD","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT06846281?term=efficacy%20and%20safety%20of%20remibrutinib%20after%20switching&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Northwestern University"},"Description\n":"Effect of Kesimpta in lactating women with MS","Condition Tag":null,"PI":"Edith Graham, MD","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT06444113?term=katharos&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Northwestern University"},"Description\n":"Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis","Condition Tag":null,"PI":"Dr. George Georges","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT04047628?term=beat-ms&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":3,"Value":"Northwestern University"},"Description\n":"Trial of Inebilizumab in NMDAR Encephalitis ","Condition Tag":null,"PI":"Dr. Elena Grebenciucova","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT04372615?term=ExTINGUISH%20Trial%20of%20Inebilizumab%20in%20NMDAR%20Encephalitis%20&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":4,"Value":"The University of Chicago"},"Description\n":"Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis","Condition Tag":null,"PI":"Dr. Veronica Cipriani","Study Coordinator":null,"Study Contact Email":null,"Link":"https://clinicaltrials.gov/study/NCT06141486?cond=Multiple%20Sclerosis&term=FREVIVA&rank=1"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Description\n":"Mood and Exercise Training Study for Multiple Sclerosis","Condition Tag":null,"PI":null,"Study Coordinator":null,"Study Contact Email":null,"Link":"https://metsforms.ahs.uic.edu/"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Description\n":"Cognition, Vascular Function, and Physical Activity in Multiple Sclerosis","Condition Tag":null,"PI":null,"Study Coordinator":null,"Study Contact Email":null,"Link":"https://go.uic.edu/pacems"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Description\n":"Walking Efficiency and Vascular Function in Multiple Sclerosis","Condition Tag":null,"PI":null,"Study Coordinator":null,"Study Contact Email":null,"Link":null},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Description\n":"Randomized Pilot Study Evaluating the Effect of a 6-Month Exercise Rehabilitation Program on Physical and Cognitive Function in Persons with MS who Use Wheelchairs as a Primary Mobility Device","Condition Tag":null,"PI":null,"Study Coordinator":null,"Study Contact Email":null,"Link":null},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Description\n":"Race, Ethnicity, and Active Lifestyle in MS","Condition Tag":null,"PI":null,"Study Coordinator":null,"Study Contact Email":null,"Link":null},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Description\n":"Behavioral Intervention for Physical Activity in Multiple Sclerosis – Cognition","Condition Tag":null,"PI":null,"Study Coordinator":null,"Study Contact Email":null,"Link":"https://bipamscognition.ahs.uic.edu/"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Description\n":"Physical Activity in Women with Multiple Sclerosis and Generalized Anxiety Disorder","Condition Tag":null,"PI":null,"Study Coordinator":null,"Study Contact Email":null,"Link":"https://www.redcap.ihrp.uic.edu/surveys/?s=4DWDHMY8MC8DDHNL"},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":5,"Value":"University of Illinois - Chicago"},"Description\n":"Knowledge and Perceptions of Exercise Training Among People Living with Multiple Sclerosis","Condition Tag":null,"PI":null,"Study Coordinator":null,"Study Contact Email":null,"Link":null},{"Study Name":null,"Institution":{"@odata.type":"#Microsoft.Azure.Connectors.SharePoint.SPListExpandedReference","Id":0,"Value":"Methodist Hospitals"},"Description\n":"Test 6","Condition Tag":null,"PI":"William Conte","Study Coordinator":null,"Study Contact Email":null,"Link":"https://chicago-ms.org"}]